The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis
- PMID: 22014021
- DOI: 10.1586/eci.11.66
The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis
Abstract
Stevens-Johnson syndrome has long been considered to resemble erythema multiforme with mucosal involvement, but is now thought to form a single disease entity with toxic epidermal necrolysis. Although Stevens-Johnson syndrome is less severe, etiology, genetic susceptibility and pathomechanism are the same for Stevens-Johnson syndrome/toxic epidermal necrolysis. The condition is mainly caused by drugs, but also by infections and probably other risk factors not yet identified. Identification of the cause is important for the individual patient and in cases of drug-induced disease withdrawal of the inducing drug(s) has an impact on the patient's prognosis. If an infectious cause is suspected, adequate anti-infective treatment is needed. Besides this, supportive management is crucial to improve the patient's state, probably more than specific immunomodulating treatments. Despite all of the therapeutic efforts, mortality is high and increases with disease severity, patients' age and underlying medical conditions. Survivors may suffer from long-term sequelae such as strictures of mucous membranes including severe eye problems.
Similar articles
-
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.Ann Allergy Asthma Immunol. 2005 Apr;94(4):419-36; quiz 436-8, 456. doi: 10.1016/S1081-1206(10)61112-X. Ann Allergy Asthma Immunol. 2005. PMID: 15875523 Review.
-
[Toxic epidermal necrolysis and Stevens-Johnson syndrome].Rev Prat. 2007 Jun 15;57(11):1165-70. Rev Prat. 2007. PMID: 17691257 Review. French.
-
Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.Dermatol Clin. 1992 Jul;10(3):571-82. Dermatol Clin. 1992. PMID: 1617814 Review.
-
Erythema multiforme: a review and contrast from Stevens-Johnson syndrome/toxic epidermal necrolysis.Dent Clin North Am. 2005 Jan;49(1):67-76, viii. doi: 10.1016/j.cden.2004.08.003. Dent Clin North Am. 2005. PMID: 15567361 Review.
-
Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.Arch Dermatol. 2009 Feb;145(2):157-62. doi: 10.1001/archdermatol.2009.540. Arch Dermatol. 2009. PMID: 19221260
Cited by
-
Early Recognition and Management of Ocular Manifestations of Toxic Epidermal Necrolysis in a Pediatric Patient: A Case Report.Cureus. 2024 Sep 27;16(9):e70323. doi: 10.7759/cureus.70323. eCollection 2024 Sep. Cureus. 2024. PMID: 39469382 Free PMC article.
-
Severe Cutaneous Adverse Reactions in Korean Pediatric Patients: A Study From the Korea SCAR Registry.Allergy Asthma Immunol Res. 2019 Mar;11(2):241-253. doi: 10.4168/aair.2019.11.2.241. Allergy Asthma Immunol Res. 2019. PMID: 30661316 Free PMC article.
-
Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options.Cureus. 2023 Jun 28;15(6):e41116. doi: 10.7759/cureus.41116. eCollection 2023 Jun. Cureus. 2023. PMID: 37519510 Free PMC article. Review.
-
The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China.J Immunol Res. 2018 Feb 11;2018:4320195. doi: 10.1155/2018/4320195. eCollection 2018. J Immunol Res. 2018. PMID: 29607330 Free PMC article.
-
Effectiveness of early treatment with plasma exchange in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.Sci Rep. 2024 Feb 5;14(1):2893. doi: 10.1038/s41598-024-53653-5. Sci Rep. 2024. PMID: 38316978 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources